Vector, Per Se (e.g., Plasmid, Hybrid Plasmid, Cosmid, Viral Vector, Bacteriophage Vector, Etc.) Bacteriophage Vector, Etc.) Patents (Class 435/320.1)
  • Patent number: 9765347
    Abstract: Provided is a transformant of S. pombe mutant which can produce and collect ?-glucosidase without requiring complicated separation steps, and a vector which is useful for transforming a yeast of the genus Schizosaccharomyces. The transformant of a S. pombe mutant of the present invention is a transformant of a Schizosaccharomyces pombe mutant which exhibits an increased Gsf activity and decreased or no pyruvyl transferase Pvg1 enzymatic activity, and is comprised of a structural gene sequence encoding a ?-glucosidase derived from a filamentous fungus, and a promoter sequence and a terminator sequence for expressing the structural gene in a chromosome or as an extrachromosomal gene. Further, the present invention relates to a cloning vector which is characterized by comprising a hsp9 gene promoter or an ihc1 gene promoter of a yeast of the genus Schizosaccharomyces, and is useful for transforming a yeast of the genus Schizosaccharomyces, an expression vector, a transformant, etc.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: September 19, 2017
    Assignee: Asahi Glass Company, Limited
    Inventors: Mayumi Kobayashi, Hideki Tohda, Shuichiro Kimura, Susumu Zen-In, Futoshi Hara
  • Patent number: 9765351
    Abstract: This invention relates to methods of controlling gene expression or gene suppression in eukaryotic cells. One aspect of this invention includes modifying the degree of silencing of a target gene by use of a modified suppression element. Another aspect includes providing a eukaryotic cell having a desired phenotype resulting from transcription in the eukaryotic cell of a modified suppression element. Also provided are transgenic eukaryotic cells, transgenic plant cells, plants, and seeds containing modified suppression elements, and useful derivatives of such transgenic plant cells, plants, or seeds, such as food or feed products.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: September 19, 2017
    Assignee: MONSANTO TECHNOLOGY LLC
    Inventors: Joanne Fillatti, Jean C. Goley, Gregory R. Heck, Tichafa R. I. Munyikwa, Ty T. Vaughn, Toni Voelker
  • Patent number: 9765332
    Abstract: The present invention relates to oligonucleotides useful for inhibiting or reducing bacterial biofilms.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: September 19, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE RENNES 1
    Inventors: Brice Felden, Valerie Bordeau
  • Patent number: 9765330
    Abstract: Allograft recognition and rejection of donor cells in a host is reduced by limiting or even abrogating expression of the donor cell's MHC-I peptides to avoid CD8+ T-cell recognition and by expression of inhibitory factors to avoid an NK cell mediated cytotoxic response.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: September 19, 2017
    Assignee: Nant Holdings IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Patrick Soon-Shiong
  • Patent number: 9765327
    Abstract: Described herein are methods and related compositions for inducing differentiation of human pluripotent stem cells (hPSCs) into hemogenic endothelium with pan-myeloid potential or restricted potential, by forced expression in the hPSCs of a combination of transcription factors as described herein.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: September 19, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Igor Slukvin, Irina Elcheva
  • Patent number: 9764044
    Abstract: The invention relates to methods of altering gene expression by homologous recombination in a multipotent adult progenitor cell (MAPC). In particular, methods of producing a recombinant MAPC, of correcting a genetic defect in a mammal, of providing a functional and/or therapeutic protein to a mammal, and of transforming a MAPC are provided. MAPCs containing an erogenous DNA as well as recombinant MAPCs and their differentiated progeny are also provided.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: September 19, 2017
    Assignee: ABT HOLDING COMPANY
    Inventors: Catherine Verfaillie, Uma Lakshmipathy
  • Patent number: 9757120
    Abstract: The present disclosure is directed to a joining element elongate in a longitudinal direction including an inner core extending substantially in the longitudinal direction and an outer sleeve surrounding at least a portion of the inner core. The sleeve includes a lattice that defines at least one angle with respect to the longitudinal direction and the core is swellable against the sleeve along a direction perpendicular to the longitudinal direction to thereby increase the angle with respect to the longitudinal direction. The disclosure is further directed to a method of joining a first a second material including the joining element of the present disclosure.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 12, 2017
    Assignee: DePuy Synthes Products, Inc.
    Inventors: Joerg Mayer, Jochen Ganz, Beat Keller, Ralph Hertel
  • Patent number: 9758563
    Abstract: An insulin analog comprises a B-chain polypeptide incorporating a chlorinated phenylalanine. The chlorinated phenylalanine may be located at position B24. The chlorinated phenylalanine may be para-monochloro-phenylalanine. The analog may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analog. The chlorinated insulin analogs retain significant activity. A method of treating a patient comprises administering a physiologically effective amount of the insulin analog or a physiologically acceptable salt thereof to a patient. Chlorine substitution-based stabilization of insulin may reduce fibrillation and thereby enhance the treatment of diabetes mellitus in regions of the developing world lacking refrigeration.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: September 12, 2017
    Assignee: Case Western Reserve University
    Inventor: Michael Weiss
  • Patent number: 9745638
    Abstract: The invention provides methods and compositions for rapid, sensitive, and highly specific nucleic acid-based (e.g., DNA based) detection of a BK virus in a sample. In general, the methods involve detecting a target nucleic acid having a target sequence of a conserved region of BK viral genomes. The invention also features compositions, including primers, probes, and kits, for use in the methods of the invention.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: August 29, 2017
    Assignee: Focus Diagnostics, Inc.
    Inventors: Fan Chen, Lilly I. Kong, Jules Chen, Mehrdad Jannatipour
  • Patent number: 9745353
    Abstract: Anti-peptide antibodies (APAs) are extremely important tools for biomedical research. Many important techniques, such as immunoblots, ELISA immunoassays, immunocytochemistry, and protein microarrays are intrinsically linked to APA function and completely dependent on APA quality. Unfortunately, not all commercially-available APAs have good antigen binding characteristics; as a result, researchers are often unable to perform high quality protein analysis experiments. This disclosure describes a new method for the scalable production of polyclonal APAs using recombinant antigens. These recombinant peptide antigens have several advantages over traditional peptide antigens which improve the ease and speed of antibody production. The recombinant antigens can be scalably produced and purified much faster than traditional synthetic peptide-conjugates.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: August 29, 2017
    Assignee: Bioo Scientific Corporation
    Inventors: Joseph Krebs, Paul Morrison, Jun Wang
  • Patent number: 9745345
    Abstract: An anti-tumor polypeptide, having an amino acid sequence represented by FPGSDRF (SEQ ID NO: 15), X-FPGSDRF (SEQ ID NO: 16), FPGSDRF-Z (SEQ ID NO: 17), or X-FPGSDRF-Z (SEQ ID NO: 18) is disclosed. The various capital letters denote amino acids: F: phenylalanine; P: proline; G: glycine; D: aspartic acid; R: arginine; S is a phosphorylated serine residue, X and Z are an amino acid residue or an amino acid sequence, respectively, X is one selected from the group consisting of F, (R)9 (SEQ ID NO: 19), (R)9-F (SEQ ID NO: 20), 6-aminocaproic acid, 6-aminocaproic acid-F, 6-aminocaproic acid-(R)9 (SEQ ID NO: 21), and 6-aminocaproic acid-(R)9-F (SEQ ID NO: 22), Z is one selected from the group consisting of A, (G)n-RGD (SEQ ID NO: 23), and A-(G)n-RGD (SEQ ID NO: 24); and n is an integer greater than or equal to 0.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: August 29, 2017
    Assignee: NANJING MEDICAL UNIVERSITY
    Inventors: Jianwei Zhou, Jin Xu, Xuan Li, Aiping Li
  • Patent number: 9745590
    Abstract: Circular nucleic acid vectors that provide for persistently high levels of protein expression are provided. The circular vectors of the subject invention are characterized by being devoid of expression-silencing bacterial sequences, where in many embodiments the subject vectors include a unidirectional site-specific recombination product hybrid sequence in addition to an expression cassette. Also provided are methods of using the subject vectors for introduction of a nucleic acid, e.g., an expression cassette, into a target cell, as well as preparations for use in practicing such methods. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications. Also provided is a highly efficient and readily scalable method for producing the vectors employed in the subject methods, as well as reagents and kits/systems for practicing the same.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: August 29, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Zhi-Ying Chen
  • Patent number: 9738900
    Abstract: The invention relates to transgenic plants with improved growth and nitrogen use efficiency expressing nitrate transporter gene, methods of making such plants and methods for improving growth and nitrogen use efficiency.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: August 22, 2017
    Assignees: Plant Bioscience Limited, Nanjing Agricultural University
    Inventors: Guohua Xu, Xiaorong Fan, Qirong Shen, Anthony Miller
  • Patent number: 9737620
    Abstract: Improved DNA vaccine plasmids are disclosed that contain novel immunostimulatory RNA compositions. The improved plasmids eliminate all extraneous sequences, incorporate a novel antibiotic free short RNA based selectable marker, increase eukaryotic expression using a novel chimeric promoter, improve yield and stability during bacterial production, and improve immunostimulation. These vectors are utilized in immunization to elicit improved immune responses or therapy to induce type 1 interferon production.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: August 22, 2017
    Assignee: NATURE TECHNOLOGY CORPORATION
    Inventor: James A. Williams
  • Patent number: 9738890
    Abstract: The present invention relates to a method based on the use of restriction enzyme digestion and ligation via cleavage sites, thereby to prepare two or more standardized expression cassettes.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: August 22, 2017
    Assignee: DSM IP ASSETS B.V.
    Inventors: Johannes Andries Roubos, Herman Jan Pel, Bernard Meijrink
  • Patent number: 9738908
    Abstract: The invention relates to engineered CRISPR/Cas9 systems for genomic modification and regulation of gene expression in mammalian cells. The specification describes the design and validation of polynucleotides encoding the Streptococcus pyogenes (S. pyogenes) Cas9 gene and protein and variants of that protein, where the nucleotide sequence has been optimized for expression in mammalian cells, and also modified by fused sequences that enhance various aspects of the CRISPR/Cas system. The specification also describes systems for RNA-guided genome engineering and gene regulation in mammalian cells, including human cells.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: August 22, 2017
    Assignee: System Biosciences, LLC
    Inventor: Fangting Wu
  • Patent number: 9732344
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: August 15, 2017
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Leonid Beigelman, James McSwiggen, Chandra Vargeese
  • Patent number: 9730435
    Abstract: Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized a proliferation-inducing ligand gene. Non-human animals and cells that express a human or humanized a proliferation-inducing ligand protein from an endogenous a proliferation-inducing ligand locus are described.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: August 15, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: John McWhirter, Cagan Gurer, Lynn Macdonald, Andrew J. Murphy
  • Patent number: 9725509
    Abstract: The invention relates to anti-human interleukin 6 antibodies and antibody fragments, nucleic acids and vectors which encode for these antibodies and antibody fragments the use thereof in therapy and diagnosis.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: August 8, 2017
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith
  • Patent number: 9724405
    Abstract: The present invention is generally related to virus-like particles (VLPs) comprising rabies virus (RV) glycoproteins (G proteins) and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rabies virus infection.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: August 8, 2017
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Ye Liu
  • Patent number: 9719069
    Abstract: Disclosed are compositions and methods that relate generally to viruses, and more particularly to the agents and their identification and use of anti-HIV agents which cause latently infected cells to reactivate.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: August 1, 2017
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Vicente Planelles, Alberto Bosque
  • Patent number: 9717781
    Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: August 1, 2017
    Inventors: Alexander Shneider, Franco Venanzi, Michael Sherman, Victor Shifrin
  • Patent number: 9719101
    Abstract: The invention relates to gene expression regulatory sequences from soybean, specifically to the promoter of a soybean eukaryotic glyceraldehyde-3-phosphate dehydrogenasegene and fragments thereof and their use in promoting the expression of one or more heterologous nucleic acid fragments in a constitutive manner in plants. The invention further discloses compositions, polynucleotide constructs, transformed host cells, transgenic plants and seeds containing the recombinant construct with the promoter, and methods for preparing and using the same.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: August 1, 2017
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventor: Zhongsen Li
  • Patent number: 9719133
    Abstract: The present invention relates to new methods and uses for the qualitative and quantitative detection of microbial nucleic acids using at least a first control nucleic acid, or a first and a second control nucleic acid in different concentrations. The method is based on amplification of nucleic acids, for example the polymerase chain reaction. Further provided are kits comprising components for performing said methods and uses.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: August 1, 2017
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Reiner Babiel, Frank Bergmann, Dorothea Sizmann
  • Patent number: 9706734
    Abstract: A novel maize variety designated PH2G46 and seed, plants and plant parts thereof are provided. Methods for producing a maize plant comprise crossing maize variety PH2G46 with another maize plant are provided. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into PH2G46 through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby are provided. Hybrid maize seed, plants or plant parts are produced by crossing the variety PH2G46 or a locus conversion of PH2G46 with another maize variety.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: July 18, 2017
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Steven Paul King, Lori Karyn Scott
  • Patent number: 9708622
    Abstract: The present invention relates to genetic constructs, which can be used in the preparation of transgenic plants. The constructs can have the ability of reducing nitrate concentration in the plant, in particular the plant's leaves, and for inducing a senescence-like phenotype. The invention extends to plant cells transformed with such constructs, and to the transgenic plants themselves. The invention also relates to methods of producing transgenic plants, and to methods of reducing nitrate content in plants. The invention also relates to harvested plant leaves, for example tobacco leaves, that have been transformed with the genetic constructs, and to various tobacco articles, such as smoking articles, comprising such harvested plant leaves.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: July 18, 2017
    Assignee: British American Tobacco (Investments) Limited
    Inventors: Susan Davenport, Pascaline Le Lay, Juan Pablo Sanchez Tamburinno
  • Patent number: 9708387
    Abstract: A process of producing heavy chain peptide and/or light chain peptide of recombinant Factor VIII protein includes using the Pichia pastoris expression system. A process of producing a functional recombinant Factor VIII protein by reconstituting the Heavy chain and Light chain produced using said Pichia pastoris expression system. The said functional recombinant Factor VIII protein shows improved activity and therefore is used in the management of haemophilia.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: July 18, 2017
    Assignee: CENTRE FOR BIOSEPARATION TECHNOLOGY-VIT
    Inventors: Vijayalakshmi Mookambeswaran Arunachalam, Vignesh Narasimhan Janakiraman, Krishnan Venkataraman, Sudheer Reddy Aswatha Reddy, Satheeshkumar Padikkara Kutty, Sukesh Chandran Nair, Alok Srivastava
  • Patent number: 9706730
    Abstract: A novel maize variety designated PH25VF and seed, plants and plant parts thereof are provided. Methods for producing a maize plant comprise crossing maize variety PH25VF with another maize plant are provided. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into PH25VF through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby are provided. Hybrid maize seed, plants or plant parts are produced by crossing the variety PH25VF or a locus conversion of PH25VF with another maize variety.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: July 18, 2017
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventor: Stephen Joseph Szalma
  • Patent number: 9699985
    Abstract: A novel maize variety designated X08F022 and seed, plants and plant parts thereof are produced by crossing inbred maize varieties. Methods for producing a maize plant by crossing hybrid maize variety X08F022 with another maize plant are disclosed. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into X08F022 through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. This invention relates to the maize variety X08F022, the seed, the plant produced from the seed, and variants, mutants, and minor modifications of maize variety X08F022. This invention further relates to methods for producing maize varieties derived from maize variety X08F022.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: July 11, 2017
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Thomas Charles Barker, Wade Eugene Odland
  • Patent number: 9701984
    Abstract: The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: July 11, 2017
    Assignee: University of Massachusetts
    Inventors: Guangping Gao, Hongwei Zhang, Hongyan Wang, Zuoshang Xu
  • Patent number: 9700023
    Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: July 11, 2017
    Assignees: DS Pharma Biomedical Co., Ltd., National Cancer Center
    Inventors: Takumi Teratani, Takahiro Ochiya
  • Patent number: 9701973
    Abstract: A method is provided for transforming monocotyledonous plants to express DNA sequences of interest from plant cell plastids. The method allows the transformation of monocot plant tissue with heterologous DNA constructs. The invention also provides for monocot cells in which the plastids contain heterologous DNA constructs.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: July 11, 2017
    Assignee: Monsanto Technology LLC
    Inventors: Vladimir Sidorov, Jeffrey M. Staub, Yuechun Wan, Guangning Ye
  • Patent number: 9693539
    Abstract: The instant invention relates to transgenic non-human animals capable of producing heterologous antibodies, transgenes used to produce such transgenic animals, transgenes capable of functionally rearranging a heterologous D gene in V-D-J recombination, immortalized B-cells capable of producing heterologous antibodies, methods and transgenes for producing heterologous antibodies of multiple isotypes, methods and transgenes for producing heterologous antibodies wherein a variable region sequence comprises somatic mutation as compared to germline rearranged variable region sequences, transgenic nonhuman animals which produce antibodies having a human primary sequence and which bind to human antigens, hybridomas made from B cells of such transgenic animals, and monoclonal antibodies expressed by such hybridomas.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: July 4, 2017
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Daniel K. Rohrer, Nancy Amelia Black, Nils Lonberg
  • Patent number: 9693530
    Abstract: The invention relates to the soybean variety designated 01063884. Provided by the invention are the seeds, plants and derivatives of the soybean variety 01063884. Also provided by the invention are tissue cultures of the soybean variety 01063884 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety 01063884 with itself or another soybean variety and plants produced by such methods.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: July 4, 2017
    Assignee: Monsanto Technology LLC
    Inventors: Craig K. Moots, David R. Wooten, Jr.
  • Patent number: 9695229
    Abstract: A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to modulation of cellular activities, including macrophage activity, and the like. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: July 4, 2017
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventor: Leland Shapiro
  • Patent number: 9686995
    Abstract: Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a Coleopteran plant pest or a Diabrotica plant pest, decrease the expression of a target sequence in the pest. In specific embodiments, the decrease in expression of the target sequence controls the pest and thereby the methods and compositions are capable of limiting damage to a plant. The present invention provides various target polynucleotides set forth in any one of SEQ ID NOS: 1-236 or active variants and fragments thereof, wherein a decrease in expression of one or more the sequences in the target pest controls the pest (i.e., has insecticidal activity). Further provided are silencing elements which when ingested by the pest decrease the level of the target polypeptide and thereby control the pest. In specific embodiment, the pest is D. virgifera virgifera, D. barberi, D. speciosa, or D. undecimpunctata howardi.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: June 27, 2017
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: Karen E. Broglie, Mani Muthalagi, Kevin Kriss, Albert L. Lu, James K. Presnail
  • Patent number: 9688731
    Abstract: Methods for obtaining highly pure native, recombinant or modified BAD-1 protein include the steps of culturing a population of microbes expressing BAD-1 protein in a culture medium, collecting the population of microbes from the culture medium, obtaining a BAD-1 protein-containing solution, and purifying the BAD-1 protein from the solution by combining the BAD-1 protein-containing solution with a nickel-chelating resin, washing the nickel-chelating resin to remove unbound matter, and eluting the BAD-1 protein from the nickel-chelating resin. Highly pure native BAD-1 protein may be used in diagnostic kits for detecting Blastomyces dermatitidis infections in animals.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: June 27, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Bruce Klein, Theodore Brandhorst
  • Patent number: 9689881
    Abstract: A method for separating target molecules or particles from a fibrinogen containing sample comprises: (a) trapping the said target molecules or particles in a fibrin network by converting at least partially the fibrinogen contained in the sample into fibrin; (b) retracting the said fibrin network to form a fibrin clot; (c) separating the said fibrin clot from the surrounding sample medium.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: June 27, 2017
    Assignee: Spinomix S.A.
    Inventors: Amar Rida, Nicolas Mermod, Patrice Francois, Vladimir Lazarevic, Jacques Schrenzel
  • Patent number: 9686926
    Abstract: According to the invention, there is provided a novel chia (Salvia hispanica L.) variety, designated Sahi Alba 914 which is independent of photoperiod, in contrast to its closest relatives. This allows the variety to be sown earlier, and to be grown at higher latitudes such as the United States. This invention thus relates to the seeds of chia (Salvia hispanica L.) variety Sahi Alba 914, to the plants of chia (Salvia hispanica L.) variety Sahi Alba 914, to plant parts of chia (Salvia hispanica L.) variety Sahi Alba 914, to methods for producing a chia (Salvia hispanica L.) variety by crossing the chia (Salvia hispanica L.) variety Sahi Alba 914 with another chia (Salvia hispanica L.) variety, and to methods for producing a chia (Salvia hispanica L.) variety containing in its genetic material one or more backcross conversion traits or transgenes and to the backcross conversion chia (Salvia hispanica L.) plants and plant parts produced by those methods.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: June 27, 2017
    Assignee: TFSB, LLC
    Inventor: Agustin Sorondo
  • Patent number: 9689000
    Abstract: The present invention relates to a gene expression regulating sequence consisting of a combination of HRE, E2F and TERT, and to a gene delivery system having significantly improved selective tumor cell cytotoxicity using same, and more particularly, to a recombinant adenovirus. In addition, the present invention relates to a pharmaceutical antitumor composition comprising the recombinant adenovirus. The replication of the recombinant adenovirus of the present invention is tumor-specifically regulated by the novel gene expression regulating sequence of the present invention, thus enabling the recombinant adenovirus of the present invention to exhibit improved selective tumor cell cytotoxicity or apoptotic potential, and exhibit remarkably improved antitumor effects particularly in hypoxic conditions. In addition, the specific expression of the recombinant adenovirus in tumor cells may increase in vivo stability, and thus may induce greatly improved antitumor effects.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: June 27, 2017
    Assignee: GENEMEDICINE CO., LTD.
    Inventors: Chae Ok Yun, A-Rum Yoon
  • Patent number: 9682154
    Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: June 20, 2017
    Assignee: Vascular Biogenics Ltd.
    Inventors: Andrea Rachel Leubitz, Naamit Sher, Erez Feige, Eyal Breitbart
  • Patent number: 9683225
    Abstract: The present invention relates to polypeptides having xylanase activity, catalytic domains, and carbohydrate binding domains, and polynucleotides encoding the polypeptides, catalytic domains, and carbohydrate binding domains. The present invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains, and carbohydrate binding domains.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: June 20, 2017
    Assignees: Novozymes, Inc., Novozymes A/S
    Inventors: Nikolaj Spodsberg, Tarana Shaghasi
  • Patent number: 9683241
    Abstract: Disclosed are polynucleotides encoding polypeptides that comprise the biosynthetic pathway for lignin in the jute plant. The present invention relates generally to the field of plant lignin biosynthesis genes, polypeptides encoded by such genes, and the use of such polynucleotide and polypeptide sequences for controlling plant lignin production. Also disclosed are methods for using the polynucleotides and polypeptides to influence the quality and amount of fiber produced by jute.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: June 20, 2017
    Assignee: Bangladesh Jute Research Institute
    Inventors: Maqsudul Alam, Haseena Khan, Mahboob Zaman, Mohammed K. Uddin, Mohammed S. Haque, Mohammed S. Islam, Muhammad S. Azam
  • Patent number: 9676817
    Abstract: The author attempted and succeeded in separating and purifying the cysteine protease inhibitors from new gingers. The root and stem of new gingers were extracted with neutral buffer which subsequently underwent heat treatment at 80° C. for 10 minutes. After centrifugal separation, the supernatant was separated with acetone. The fractions that precipitated at an acetone concentration of 55-77% were injected into a chromatographic column of DEAE-cellulose and Sephadex G-75 gel for purification. The results demonstrated that there were two cysteine protease inhibitors with a molecular weight of 11,000-11,800 and 15,500-16,000, respectively, which strongly inhibit papain. The two cysteine protease inhibitors do not have high heat stability.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: June 13, 2017
    Inventors: Poul Johansen, Cecilia Jansson Kepka
  • Patent number: 9675027
    Abstract: According to the invention, there is provided seed and plants of the corn variety designated CV031874. The invention thus relates to the plants, seeds and tissue cultures of the variety CV031874, and to methods for producing a corn plant produced by crossing a corn plant of variety CV031874 with itself or with another corn plant, such as a plant of another variety. The invention further relates to corn seeds and plants produced by crossing plants of variety CV031874 with plants of another variety, such as another inbred line. The invention further relates to the inbred and hybrid genetic complements of plants of variety CV031874.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: June 13, 2017
    Assignee: Monsanto Technology LLC
    Inventor: Marvin L. Boerboom
  • Patent number: 9676834
    Abstract: Embodiments of the invention provide to fibulin 3 (also referred to as EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1)) polypeptide variants, and nucleotide sequences that code for them, characterized by having one or more activities of inhibiting cancer growth, inhibiting cancer cell invasion, and inhibiting cancer recurrence.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: June 13, 2017
    Inventor: Yihong Zhou
  • Patent number: 9668502
    Abstract: The invention overcomes the deficiencies of the art by providing a soybean plant with non-transgenic mutations conferring decreased ?-subunit of ?-conglycinin content and increased ??-subunit content of ?-conglycinin in seed. Moreover, the invention provides an agronomically elite soybean plant with non-transgenic mutations conferring a gyclinin null phenotype, increased ?-conglycinin content, and increased ??-subunit content of ?-conglycinin in the seed. The invention also provides derivatives, and plant parts of these plants and uses thereof. Methods for producing such plants are also provided.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: June 6, 2017
    Assignee: Monsanto Technology LLC
    Inventors: Neal Bringe, Jonathan Jenkinson
  • Patent number: 9670496
    Abstract: Methods and means are provided to modify in a targeted manner the genome of a plant in close proximity to an existing elite event using a double stranded DNA break inducing enzyme. Also provided are plants, in particular cotton plants showing tolerance to a field dose of at least 1× of at least one HPPD inhibitor, and methods for making such plants.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: June 6, 2017
    Assignees: Bayer CropScience N.V., Bayer CropScience AG, Bayer CropScience LP
    Inventors: Kathleen D'Halluin, Jan Dittgen, Stefan Jansens, Frank Meulewaeter, Koen Weterings, Hal Moser, Thomas Wilde, Ruediger Hain, Udo Bickers, Linda Trolinder, Gary Henniger
  • Patent number: 9663790
    Abstract: The present invention is directed to constructs, compositions and methods for modulating platelet-type 12 lipoxygenase (12-LO) in adipose tissue in vivo. Specifically, the invention provides constructs encoding expression-inhibiting oligonucleic acids, e.g. antisense and RNA interfering (RNAi) molecules, targeted to a platelet-type 12-LO gene or a transcript thereof, which are capable of reducing or silencing platelet-type 12-LO expression specifically in adipocytes and pre-adipocytes. Vectors comprising these constructs (including, but not limited to, viral vectors), compositions comprising them and methods of using same for the treatment and amelioration of conditions associated with excess fat cell mass and obesity are also provided.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: May 30, 2017
    Assignee: The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center
    Inventors: Gary Weisinger, Rona Limor, Naftali Stern
  • Patent number: 9663716
    Abstract: A compound represented by formula (1-1) or (1-2) is provided. For example, R1 and R2 are independently hydrogen, alkyl having 1 to 10 carbons or alkoxy having 1 to 9 carbons; the ring A1, the ring A2, the ring A3, the ring A4, the ring A5 and the ring A6 are independently 1,4-cyclohexylene or 1,4-phenylene; a, b, c, d, e and f are independently 0 or 1, and the sum of a, b, c, d, e and f is 2; and g, h, i, j, k and l are independently 0 or 1, and the sum of g, h, i, j, k and l is 2.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: May 30, 2017
    Assignees: JNC CORPORATION, JNC PETROCHEMICAL CORPORATION
    Inventors: Tokifumi Masukawa, Kenji Hirata, Junichi Yamashita